$SMFR News
Last published 3y ago
- 3y agoSMFRSMFRWWGSSema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 GuidanceGlobeNewswireCompany expects to exceed 2022 revenue target with strong momentum to deliver continued growth in 2023 combining GeneDx and Centrellis® platforms Company's common stock will trade on the Nasdaq under new ticker
- 3y agoSMFRSMFRWSema4|GeneDx to Participate in the 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewswireSTAMFORD, Conn., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced the company will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco.
- 3y agoSMFRSMFRWNew Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICUGlobeNewswireSTAMFORD, Conn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced the results of a new study on mitochondrial diseases in newborns. The findings support the addition of
- 3y agoSMFRSMFRWSema4 Reports Third Quarter 2022 Financial Results and New Strategic DirectionGlobeNewswireCompany will focus on its high growth, high margin pediatric and rare disease business, powered by whole exome/genome diagnostic testing and analysis and data-driven insights from Centrellis® 19% pro forma1
- 4y agoSMFRSMFRWSema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022GlobeNewswireSTAMFORD, Conn., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced it will release financial results for the third quarter of 2022 before the market opens on Monday,
- 4y agoSMFRSMFRWSema4|GeneDx Commends New Evidence-Based Guidelines from the National Society of Genetic Counselors Recommending Exome Sequencing as a First-Tier Genetic Test for Unexplained EpilepsiesGlobeNewswireSTAMFORD, Conn., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, supports the new National Society of Genetic Counselors guidelines recommending exome sequencing as a first-tier
- 4y agoSMFRSMFRWSema4|GeneDx Announces Results from Phase 1 of SeqFirst Study, Demonstrating Broad Utility of Rapid Whole Genome Sequencing for Critically Ill NewbornsGlobeNewswire-- Abnormal findings reported in 63% of infants in study, change in health management recommended in 88% of cases ---- Sema4|GeneDx contributes to latest data in the SeqFirst study being presented at the American
- 4y agoSMFRSMFRWSema4|GeneDx collaborates on new research demonstrating genome and exome sequencing deliver more diagnostic certainty than multi-gene panelsGlobeNewswireSTAMFORD, Conn., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, has collaborated on research debunking a commonly held belief that exome and genome sequencing deliver more
- 4y agoSMFRSMFRWStudy Demonstrates the Utility of Exome Sequencing for Diagnosing Autism Spectrum DisordersGlobeNewswireResearch from 19,000 patients with Autism Spectrum Disorders found approximately 90% had prior negative tests, likely contributing to a longer time to diagnosis Data will be presented at the Child Neurology Society
- 4y agoSMFRSMFRWSema4|GeneDx To Provide Whole Genome Sequencing and Interpretation Services for Landmark Genomic Newborn Screening StudyGlobeNewswireSTAMFORD, Conn., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced it is a partner in the recently launched GUARDIAN study (Genomic Uniform-screening Against Rare Diseases In All Newborns), a collaboratio
- 4y agoSMFRSecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sema4 To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / October 4, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sema4 Holdings Corp. ("Sema4" or the "Company") (NASDAQ:SMFR) and reminds investors of the November 7, 2
- 4y agoSMFRSecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sema4 To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / September 29, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sema4 Holdings Corp. ("Sema4" or the "Company") (NASDAQ:SMFR) and reminds investors of the November
- 4y agoSMFRSecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sema4 To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / September 27, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sema4 Holdings Corp. ("Sema4" or the "Company") (NASDAQ:SMFR) and reminds investors of the November 7
- 4y agoSMFRSecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sema4 To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / September 22, 2022 / ACCESSWIRE / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sema4 Holdings Corp. ("Sema4" or the "Company") (NASDAQ:SMFR) and reminds investors of t
- 4y agoSMFRSecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sema4 To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / September 21, 2022 / Accesswire / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sema4 Holdings Corp. ("Sema4" or the "Company") (NASDAQ:SMFR) and reminds investors of t
- 4y agoSMFRSecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sema4 To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / September 15, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sema4 Holdings Corp. ("Sema4" or the "Company") (NASDAQ:SMFR) and reminds investors of the November 7
- 4y agoSMFRSema4 Holdings Corp. Stock News: Robbins LLP is Investigating Sema4 Holdings Corp. (SMFR) on Behalf of ShareholdersBusiness WireShareholder rights law firm Robbins LLP is investigating Sema4 Holdings Corp. (NASDAQ:SMFR) and its officers and directors to determine whether they violated securities laws or breached fiduciary duties in failing to disclose it would reverse a material
- 4y agoSMFRSecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sema4 To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / September 13, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sema4 Holdings Corp. ("Sema4" or the "Company") (NASDAQ:SMFR) and reminds investors of the November
- 4y agoSMFRSecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sema4 To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / September 8, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sema4 Holdings Corp. ("Sema4" or the "Company") (NASDAQ:SMFR) and reminds investors of the November 7,
- 4y agoSMFRSecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sema4 To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / September 7, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sema4 Holdings Corp. ("Sema4" or the "Company") (NASDAQ:SMFR) and reminds investors of the November 7,
- 4y agoSMFRSMFRWSecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Sema4 To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / September 4, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sema4 Holdings Corp. ("SMFR" or the "Company") (NASDAQ:SMFR)(NASDAQ:SMFRW). If you suffered losses ex
- 4y agoSMFRSecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Sema4 To Contact Him Directly To Discuss Their OptionsACCESS NewswireNEW YORK, NY / ACCESSWIRE / September 2, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sema4 Holdings Corp. ("SMFR" or the "Company") (NASDAQ:SMFR, SMFRW))). If you suffered losses exceed
- 4y agoSMFRSMFRWSema4 Appoints Healthcare and Diagnostics Industry Veteran Kevin Feeley as Chief Financial OfficerGlobeNewswireSTAMFORD, Conn., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced that the Company has appointed Kevin Feeley as Chief Financial Officer (CFO), completing its previously announced search for the CFO posi
- 4y agoSMFRSMFRWSema4 Announces Changes to its Research & Development LeadershipGlobeNewswireFounder Eric Schadt steps down from the organization, including his role as President & Chief R&D Officer Matthew Davis named Chief Technology & Product Officer to further drive the company's mission to unlock insights from data, leading to health
- 4y agoSMFRSMFRWSema4 Announces Continued Restructuring, Business Highlights, and Reports Second Quarter 2022 Financial ResultsGlobeNewswireNew management team implements significant restructuring to focus on profitable growth, efficiency, and scale 19% pro forma1 volume growth vs. 2Q 2021 Sema4 to host a conference call today at 4:30 p.m. ET STAMFORD, Conn., Aug. 15, 2
- 4y agoSMFRSMFRWSema4 to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022GlobeNewswireSTAMFORD, Conn., July 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for the second quarter of 2022 after the market close on Mon
- 4y agoSMFRSMFRWSema4 Announces Chief Financial Officer Transition PlanGlobeNewswireAppoints Richard Miao, Sema4's Deputy Chief Financial Officer, as interim Chief Financial Officer Reiterates the financial guidance provided on May 12, 2022 STAMFORD, Conn., June 14, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), an AI-driven geno
- 4y agoSMFRSMFRWAvera Health and Sema4 Announce Data-driven Study to Advance Cancer Treatment Across the Avera Service AreaGlobeNewswireSIOUX FALLS, S.D. and STAMFORD, Conn., June 01, 2022 (GLOBE NEWSWIRE) -- Avera Health, an integrated regional health care system that serves 300 locations across the Upper Midwest, and Sema4 (NASDAQ:SMFR), an AI-driven genomic and clinical data intelli
- 4y agoSMFRSMFRWSema4 to Participate at Two Investor Conferences in June 2022GlobeNewswireSTAMFORD, Conn., May 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that company management will participate at the following investor conferences: Conference:
- 4y agoSMFRSMFRWSema4 Reports First Quarter 2022 Financial Results and Business HighlightsGlobeNewswireTotal revenue of $53.9 million 1,300 basis points of sequential adjusted gross margin improvement Reaffirming full year 2022 pro forma revenue target New operating model and focus on efficiencies to reduce 2022 cash burn by an estimated $50 mill
- 4y agoHPKICPTSMFRTNXP+1Thinking about buying stock in TPI Composites, Sema4 Holdings, Highpeak Energy, Intercept Pharmaceuticals, or Tonix Pharmaceuticals?PR NewswireNEW YORK, May 6, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TPIC, SMFR, HPK, ICPT, and TNXP. To
- 4y agoSMFRSMFRWSema4 Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSTAMFORD, Conn., May 04, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that, effective as of May 2, 2022, the compensation committee of Sema4's board of directors gra
- 4y agoOPKSMFRSMFRWSema4 Announces the Completion of the GeneDx Acquisition and a Streamlined Leadership Structure to Accelerate Growth of its Diagnostic and Clinical Data PlatformsGlobeNewswireAcquisition creates an AI-driven advanced health intelligence company, now leveraging one of the largest genomic testing platforms in the U.S. Katherine Stueland, former President and CEO of GeneDx, joins Sema4 as CEO and will serve on Board of Direct
- 4y agoSMFRSMFRWSema4 to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022GlobeNewswireSTAMFORD, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for the first quarter of 2022 after the market close on Thu
- 4y agoSMFRSMFRWSema4 Achieves HITRUST CSF CertificationGlobeNewswireSTAMFORD, Conn., April 06, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that its health intelligence platform, Centrellis®, has earned Certified status for informat
- 4y agoSMFRSMFRWSema4 and Mount Sinai Use Integrative Network Analysis to Identify Potential New Lung Cancer TherapyGlobeNewswireSTAMFORD, Conn., April 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), an artificial intelligence (AI)-driven genomic and clinical data intelligence platform company, and researchers from the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai
- 4y agoSMFRSMFRWSema4 Announces Nationwide Expansion of Disparity Study to Deliver Precision Oncology Care to Underserved CommunitiesGlobeNewswire- The REPRESENT Study Will Create One of the Most Diverse and Comprehensive Clinico-genomic Datasets to Uncover and Address Disparities in Cancer Care - Sema4's Chief Medical Science Officer Will Discuss the Study at the Community Oncology Alliance's
- 4y agoCMLFSMFRSMFRWSema4 Reports Fourth Quarter and Full Year 2021 Financial Results and Business HighlightsGlobeNewswire37% increase in fourth quarter test volumes (excluding COVID-19 tests) compared to the same period last year Record quarterly test volume of nearly 83,000 24% growth in fourth quarter revenue (excluding COVID-19 tests) compared to the same period l
- 4y agoSMFRSMFRWSema4 Named to Fast Company's Annual List of the World's Most Innovative Companies for 2022GlobeNewswireSTAMFORD, Conn., March 08, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), an AI-driven genomic and clinical data intelligence platform company, has been named to Fast Company's prestigious annual list of the World's Most Innovative Companies for 2022.
- 4y agoSMFRSMFRWSema4 to Report Fourth Quarter and Full Year 2021 Financial Results and Participate in Investor Conferences in March 2022GlobeNewswireSTAMFORD, Conn., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for the fourth quarter and full year 2021 after the market c
- 4y agoSMFRSMFRWSema4 and BioSymetrics Partner on Data-Driven Drug Discovery to Advance Precision MedicineGlobeNewswireSTAMFORD, Conn. and BOSTON and TORONTO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), an AI-driven genomic and clinical data intelligence platform company, and BioSymetrics, a phenomics-driven drug discovery company, today announced a strategi
- 4y agoSMFRSMFRWSema4 to Participate at Two Upcoming Investor Conferences in FebruaryGlobeNewswireSTAMFORD, Conn., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that company management will participate at the following virtual investor conferences: BT
- 4y agoSMFRSMFRWSema4 Announces Plans to Strengthen its Market Access Team to Drive Improved Commercial and Reimbursement CapabilitiesGlobeNewswireSTAMFORD, Conn., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced plans to strengthen its Market Access team to drive increased market access for the company's
- 4y agoMGTAOPKSMFRSMFRWSema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data PlatformGlobeNewswireBusiness combination projected to deliver $350 million in pro forma 2022 revenue $200 million private placement from leading growth and life sciences investors, including Pfizer, will fortify transaction and Sema4 balance sheet Katherine Stueland,
- 4y agoSMFRSMFRWSema4 Announces Preliminary Revenue for the Fourth Quarter and Fiscal Year 2021GlobeNewswireSTAMFORD, Conn., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced preliminary revenue (unaudited) for the fourth quarter and fiscal year ended December 31, 2021
- 4y agoSMFRSMFRWSema4 to Participate at the 40th Annual J.P. Morgan Healthcare Conference in JanuaryGlobeNewswireSTAMFORD, Conn., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that Eric Schadt, PhD, Founder and Chief Executive Officer, and Isaac Ro, Chief Financial Offi
- 4y agoSMFRSMFRWSema4 Reports Third Quarter 2021 Financial Results and Business HighlightsGlobeNewswire36% increase in test volume (excluding COVID-19 tests) compared to the same period last year 17% growth in revenue (excluding COVID-19 tests) compared to the same period last year Full year 2021 total revenue guidan
- 5y agoSMFRSMFRWSema4 and Mount Sinai use Machine Learning to Improve Postpartum Hemorrhage Risk PredictionGlobeNewswireSTAMFORD, Conn., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), an AI-driven genomic and clinical data intelligence platform company, recently published two studies demonstrating the utility of machine learning to predict clinical outcomes for
- 5y agoSMFRSMFRWSema4 to Participate at Three Upcoming Investor Conferences in NovemberGlobeNewswireSTAMFORD, Conn., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that company management will participate at the following virtual investor conferences: St
- 5y agoSMFRSMFRWSema4 to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021GlobeNewswireSTAMFORD, Conn., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for the third quarter of 2021 after the market close on Mond